Company Overview and News

 
Solid Energy creditors to get at least 60 cents in $1 as assets sold

2017-11-14 nzherald.co.nz
Solid Energy New Zealand's creditors will get at least 60 cents in the dollar after the failed state-owned enterprise's mines are sold, up from the previous range of 45 cents to 55 cents.

 
Brian Gaynor: Miner's end leaves taxpayers in a hole

2017-10-06 nzherald.co.nz
The sale of Solid Energy's remaining operating coalmines terminates the Crown's 114-year involvement in the coal industry.

 
Coal makes minor comeback as hydro power dries up

2017-06-19 radionz.co.nz
The much-criticised coal industry is making a minor comeback in New Zealand as dry weather deprives hydro dams of water in the South Island.

 
Council rescinds decision on Te Kuha coal mine after Forest & Bird legal action

2017-04-13 nzherald.co.nz
Legal action by Forest & Bird (F&B) has prompted a U-turn from the Buller District Council over the proposed Te Kuha coal mine.

 
Bathurst Resources finds replacement for lost contract

2017-04-06 nzherald.co.nz
Bathurst Resources has found a new buyer for coal from its Canterbury mine, replacing the lost supply deal for Westport's cement works when Holcim closed the plant last year.

 
Solid Energy announces closure of mothballed Spring Creek Mine after failing to find a buyer

2017-02-03 nzherald.co.nz
Solid Energy has announced the closure of the Spring Creek Mine after failing to find a buyer, closing the door on one of the best coal resources in New Zealand - and 150 years of underground mining on the West Coast.

 
Bathurst Resources sued for US$40m by L&M Coal Holdings

2016-12-22 nzherald.co.nz
Coalminer Bathurst Resources Ltd (BRL) is being sued for US$40 million (NZ$53.7m) by L&M Coal Holdings Ltd (LMCH).

 
Bioenergy sector concedes heat still left in coal industry

2016-11-02 radionz.co.nz
Bioenergy industry players have conceded that a revived coal industry will continue to provide energy for industry for years to come, especially in the South Island.

 
$46m up-front payment for Solid Energy's coal mines

2016-11-02 radionz.co.nz
The buyers of Solid Energy's main coal mines will pay $46 million up front, and could pay as much as $50m extra if coal prices rise.

 
Phoenix to pay $46m for West Coast coal mines

2016-11-02 nzherald.co.nz
Phoenix Coal has agreed to pay $46 million cash for Solid Energy's Stockton, Rotowaro and Maramarua mines, plus a 'contingent payment', Bathurst Resources revealed today.

 
Phoenix Coal, Solid Energy agree to mine purchases

2016-11-02 newshub.co.nz
The Bathurst Resources and Talley's Group joint venture, Phoenix Coal, is to pay $46 million to buy Solid Energy's Stockton, Rotowaro and Maramarua Mines.

 
Solid Energy mines sold to Bathurst-Talley's venture

2016-11-01 radionz.co.nz
Three coal mines of the collapsed state firm Solid Energy are to be sold to a joint venture.

 
Solid Energy sale 'will be some relief' - John Key

2016-10-31 newshub.co.nz
Prime Minister John Key says the sale of Solid Energy's mines on the West Coast and Waikato is good news for communities.

 
Solid Energy mines sold

2016-10-31 newshub.co.nz
The Government says the sale of Solid Energy's assets is the "best outcome" it could've hoped for.

 
Solid Energy mines sold to Bathhurst-Talley's venture

2016-10-30 radionz.co.nz
Three coal mines of the collapsed state firm Solid Energy are to be sold to a joint venture.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...